310 related articles for article (PubMed ID: 29628435)
1. Dependence on the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant KRAS-Driven Cancers.
Koundinya M; Sudhalter J; Courjaud A; Lionne B; Touyer G; Bonnet L; Menguy I; Schreiber I; Perrault C; Vougier S; Benhamou B; Zhang B; He T; Gao Q; Gee P; Simard D; Castaldi MP; Tomlinson R; Reiling S; Barrague M; Newcombe R; Cao H; Wang Y; Sun F; Murtie J; Munson M; Yang E; Harper D; Bouaboula M; Pollard J; Grepin C; Garcia-Echeverria C; Cheng H; Adrian F; Winter C; Licht S; Cornella-Taracido I; Arrebola R; Morris A
Cell Chem Biol; 2018 Jun; 25(6):705-717.e11. PubMed ID: 29628435
[TBL] [Abstract][Full Text] [Related]
2. CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.
Costa-Cabral S; Brough R; Konde A; Aarts M; Campbell J; Marinari E; Riffell J; Bardelli A; Torrance C; Lord CJ; Ashworth A
PLoS One; 2016; 11(2):e0149099. PubMed ID: 26881434
[TBL] [Abstract][Full Text] [Related]
3. Scaffold repurposing of fendiline: Identification of potent KRAS plasma membrane localization inhibitors.
Wang P; van der Hoeven D; Ye N; Chen H; Liu Z; Ma X; Montufar-Solis D; Rehl KM; Cho KJ; Thapa S; Chen W; van der Hoeven R; Frost JA; Hancock JF; Zhou J
Eur J Med Chem; 2021 May; 217():113381. PubMed ID: 33756124
[TBL] [Abstract][Full Text] [Related]
4. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors.
Vyas VK; Ghate M
Mini Rev Med Chem; 2011 Oct; 11(12):1039-55. PubMed ID: 21861807
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous inhibition of PFKFB3 and GLS1 selectively kills KRAS-transformed pancreatic cells.
Ozcan SC; Mutlu A; Altunok TH; Gurpinar Y; Sarioglu A; Guler S; Muchut RJ; Iglesias AA; Celikler S; Campbell PM; Yalcin A
Biochem Biophys Res Commun; 2021 Sep; 571():118-124. PubMed ID: 34325126
[TBL] [Abstract][Full Text] [Related]
6. Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors.
Kazi A; Xiang S; Yang H; Chen L; Kennedy P; Ayaz M; Fletcher S; Cummings C; Lawrence HR; Beato F; Kang Y; Kim MP; Delitto A; Underwood PW; Fleming JB; Trevino JG; Hamilton AD; Sebti SM
Clin Cancer Res; 2019 Oct; 25(19):5984-5996. PubMed ID: 31227505
[TBL] [Abstract][Full Text] [Related]
7. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors.
Berry W; Algar E; Kumar B; Desmond C; Swan M; Jenkins BJ; Croagh D
Int J Cancer; 2017 May; 140(10):2331-2343. PubMed ID: 28198009
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia.
Sykes DB; Kfoury YS; Mercier FE; Wawer MJ; Law JM; Haynes MK; Lewis TA; Schajnovitz A; Jain E; Lee D; Meyer H; Pierce KA; Tolliday NJ; Waller A; Ferrara SJ; Eheim AL; Stoeckigt D; Maxcy KL; Cobert JM; Bachand J; Szekely BA; Mukherjee S; Sklar LA; Kotz JD; Clish CB; Sadreyev RI; Clemons PA; Janzer A; Schreiber SL; Scadden DT
Cell; 2016 Sep; 167(1):171-186.e15. PubMed ID: 27641501
[TBL] [Abstract][Full Text] [Related]
9. An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors.
Indarte M; Puentes R; Maruggi M; Ihle NT; Grandjean G; Scott M; Ahmed Z; Meuillet EJ; Zang S; Lemos R; Du-Cuny L; Layng FIAL; Correa RG; Bankston LA; Liddington RC; Kirkpatrick L; Powis G
Cancer Res; 2019 Jun; 79(12):3100-3111. PubMed ID: 31040156
[TBL] [Abstract][Full Text] [Related]
10. A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS.
Pang X; Liu M
Chin J Cancer; 2016 Oct; 35(1):92. PubMed ID: 27793187
[TBL] [Abstract][Full Text] [Related]
11. A carboxylic acid isostere screen of the DHODH inhibitor Brequinar.
DeRatt LG; Christine Pietsch E; Tanner A; Shaffer P; Jacoby E; Wang W; Kazmi F; Zhang X; Attar RM; Edwards JP; Kuduk SD
Bioorg Med Chem Lett; 2020 Nov; 30(22):127589. PubMed ID: 33007394
[TBL] [Abstract][Full Text] [Related]
12. Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer.
Madak JT; Bankhead A; Cuthbertson CR; Showalter HD; Neamati N
Pharmacol Ther; 2019 Mar; 195():111-131. PubMed ID: 30347213
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the de novo pyrimidine biosynthesis pathway limits ribosomal RNA transcription causing nucleolar stress in glioblastoma cells.
Lafita-Navarro MC; Venkateswaran N; Kilgore JA; Kanji S; Han J; Barnes S; Williams NS; Buszczak M; Burma S; Conacci-Sorrell M
PLoS Genet; 2020 Nov; 16(11):e1009117. PubMed ID: 33201894
[TBL] [Abstract][Full Text] [Related]
14. ENT1 blockade by CNX-774 overcomes resistance to DHODH inhibition in pancreatic cancer.
Mullen NJ; Thakur R; Shukla SK; Chaika NV; Kollala SS; Wang D; He C; Fujii Y; Sharma S; Mulder SE; Sykes DB; Singh PK
Cancer Lett; 2023 Jan; 552():215981. PubMed ID: 36341997
[TBL] [Abstract][Full Text] [Related]
15. Targeting mutated GTPase KRAS in tumor therapies.
Fan G; Lou L; Song Z; Zhang X; Xiong XF
Eur J Med Chem; 2021 Dec; 226():113816. PubMed ID: 34520956
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and pharmacological evaluation of novel substituted quinoline-2-carboxamide derivatives as human dihydroorotate dehydrogenase (hDHODH) inhibitors and anticancer agents.
Vyas VK; Variya B; Ghate MD
Eur J Med Chem; 2014 Jul; 82():385-93. PubMed ID: 24929289
[TBL] [Abstract][Full Text] [Related]
17. Multidimensional Screening Platform for Simultaneously Targeting Oncogenic KRAS and Hypoxia-Inducible Factors Pathways in Colorectal Cancer.
Bousquet MS; Ma JJ; Ratnayake R; Havre PA; Yao J; Dang NH; Paul VJ; Carney TJ; Dang LH; Luesch H
ACS Chem Biol; 2016 May; 11(5):1322-31. PubMed ID: 26938486
[TBL] [Abstract][Full Text] [Related]
18. Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer.
Blake DR; Vaseva AV; Hodge RG; Kline MP; Gilbert TSK; Tyagi V; Huang D; Whiten GC; Larson JE; Wang X; Pearce KH; Herring LE; Graves LM; Frye SV; Emanuele MJ; Cox AD; Der CJ
Sci Signal; 2019 Jul; 12(590):. PubMed ID: 31311847
[TBL] [Abstract][Full Text] [Related]
19. The dihydroorotate dehydrogenases: Past and present.
Reis RAG; Calil FA; Feliciano PR; Pinheiro MP; Nonato MC
Arch Biochem Biophys; 2017 Oct; 632():175-191. PubMed ID: 28666740
[TBL] [Abstract][Full Text] [Related]
20. Synthetic Lethal Vulnerabilities in
Aguirre AJ; Hahn WC
Cold Spring Harb Perspect Med; 2018 Aug; 8(8):. PubMed ID: 29101114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
